381 related articles for article (PubMed ID: 27608016)
1. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.
Pinto MP; Sotomayor P; Carrasco-Avino G; Corvalan AH; Owen GI
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608016
[TBL] [Abstract][Full Text] [Related]
2. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
3. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis: a target for cancer therapy.
Tortora G; Melisi D; Ciardiello F
Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402
[TBL] [Abstract][Full Text] [Related]
5. The great escape; the hallmarks of resistance to antiangiogenic therapy.
van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
[TBL] [Abstract][Full Text] [Related]
6. The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.
Shao Y; Lu B
Cancer Metastasis Rev; 2022 Mar; 41(1):173-191. PubMed ID: 34664157
[TBL] [Abstract][Full Text] [Related]
7. Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.
Pezzella F; Ribatti D
Cancer Rep (Hoboken); 2022 Dec; 5(12):e1318. PubMed ID: 33295149
[TBL] [Abstract][Full Text] [Related]
8. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN; Coleman RL; Sood AK
J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
[TBL] [Abstract][Full Text] [Related]
9. Natural Products with Antiangiogenic and Antivasculogenic Mimicry Activity.
Guan YY; Luan X; Lu Q; Liu YR; Sun P; Zhao M; Chen HZ; Fang C
Mini Rev Med Chem; 2016; 16(16):1290-1302. PubMed ID: 26864555
[TBL] [Abstract][Full Text] [Related]
10. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
11. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective.
Rivera L; Pandika M; Bergers G
Adv Exp Med Biol; 2014; 772():83-99. PubMed ID: 24272355
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
14. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
15. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
16. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
17. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
18. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
19. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
[TBL] [Abstract][Full Text] [Related]
20. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
